Cardiac Toxicity of Adjuvant Systemic Therapy for Early-Stage Breast Cancer
Author Information
Author(s): K. Towns, P.L. Bedard, S. Verma
Primary Institution: University of Toronto, Sunnybrook Odette Cancer Centre
Hypothesis
What are the risks of cardiac toxicity associated with adjuvant systemic therapy for early-stage breast cancer?
Conclusion
Adjuvant systemic therapies for early-stage breast cancer can lead to significant cardiac toxicity, necessitating careful monitoring and management.
Supporting Evidence
- Breast cancer is the most common malignancy in women, with significant advances in treatment leading to improved survival rates.
- Cardiac toxicity is a major concern with adjuvant therapies like anthracyclines and trastuzumab.
- Monitoring left ventricular function is crucial for patients receiving potentially cardiotoxic therapies.
Takeaway
Some treatments for breast cancer can hurt your heart, so doctors need to be careful and check how your heart is doing while you get treated.
Methodology
The article reviews existing literature on cardiac toxicity risks and strategies to minimize cardiac morbidity associated with various therapies.
Limitations
The article does not provide new clinical trial data but summarizes existing studies, which may have varying definitions and criteria for cardiac toxicity.
Participant Demographics
The article discusses women diagnosed with early-stage breast cancer, particularly focusing on older women and those receiving specific therapies.
Want to read the original?
Access the complete publication on the publisher's website